These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6850667)

  • 41. Teniposide in epithelial ovarian carcinoma: a phase II trial of the Gynecologic Oncology Group.
    Muss H; Bundy BN; DiSaia PJ; Twiggs LB
    Cancer Treat Rep; 1986 Oct; 70(10):1231-2. PubMed ID: 3530450
    [No Abstract]   [Full Text] [Related]  

  • 42. Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC).
    Chapman R; Itri L; Gralla R; Kelsen D; Casper E; Golbey R
    Cancer Chemother Pharmacol; 1982; 7(2-3):205-7. PubMed ID: 7083460
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral etoposide for patients with metastatic gastric adenocarcinoma.
    Ajani JA; Mansfield PF; Dumas P
    Cancer J Sci Am; 1999; 5(2):112-4. PubMed ID: 10198733
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase II trial of VP 16-213 in adults with refractory acute myeloid leukemia. An Eastern Cooperative Oncology Group study.
    Bennett JM; Lymann GH; Cassileth PA; Glick JH; Oken MM
    Am J Clin Oncol; 1984 Oct; 7(5):471-3. PubMed ID: 6594926
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase II study of oral VP-16-213 in hepatocellular carcinoma.
    Cavalli F; Rozencweig M; Renard J; Goldhirsch A; Hansen HH
    Eur J Cancer Clin Oncol; 1981 Oct; 17(10):1079-82. PubMed ID: 6279406
    [No Abstract]   [Full Text] [Related]  

  • 46. Stevens-Johnson syndrome associated with etoposide therapy.
    Jameson CH; Solanki DL
    Cancer Treat Rep; 1983 Nov; 67(11):1050-1. PubMed ID: 6640556
    [No Abstract]   [Full Text] [Related]  

  • 47. A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma.
    Spiridonidis CH; Laufman LR; Jones JJ; Gray DJ; Cho CC; Young DC
    Cancer; 1996 Nov; 78(10):2070-7. PubMed ID: 8918399
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Etoposide in the treatment of multifocal eosinophilic granuloma.
    Urbano-Márquez A; Estruch R; Fernandez-Huerta JM; Montserrat E; Rozman C
    Cancer Treat Rep; 1985 Feb; 69(2):238-9. PubMed ID: 3971395
    [No Abstract]   [Full Text] [Related]  

  • 49. [Fluorouracil, mitomycin-C and adriamycin in the treatment of metastasizing gastrointestinal adenocarcinomas].
    Späti B; Jungi WF; Mayr AC; Hammer B; Senn HJ
    Schweiz Med Wochenschr; 1980 Jul; 110(27-28):1076-8. PubMed ID: 7423154
    [TBL] [Abstract][Full Text] [Related]  

  • 50. VP16-213 as a single agent in advanced testicular tumors.
    Fitzharris BM; Kaye SB; Saverymuttu S; Newlands ES; Barrett A; Peckham MJ; McElwain TJ
    Eur J Cancer (1965); 1980 Sep; 16(9):1193-7. PubMed ID: 7227446
    [No Abstract]   [Full Text] [Related]  

  • 51. Phase II trial of etoposide in the management of advanced and recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group Study.
    Slayton RE; Blessing JA; Angel C; Berman M
    Cancer Treat Rep; 1987 Dec; 71(12):1303-4. PubMed ID: 3690545
    [No Abstract]   [Full Text] [Related]  

  • 52. Lack of severe hypotension with VP-16-213 administered directly lv.
    Cavalli F; Sonntag RW; Ryssel HJ; Brunner KW
    Cancer Treat Rep; 1977 Oct; 61(7):1411. PubMed ID: 589604
    [No Abstract]   [Full Text] [Related]  

  • 53. Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma: a southwest oncology group study.
    Poplin EA; Liu PY; Delmore JE; Wilczynski S; Moore DF; Potkul RK; Fine BA; Hannigan EV; Alberts DS
    Gynecol Oncol; 1999 Sep; 74(3):432-5. PubMed ID: 10479505
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [New antineoplastic drugs of the podophyllotoxin derivative group].
    Robak T; Płuzańska A
    Pol Tyg Lek; 1983 Jan; 38(1):27-30. PubMed ID: 6346283
    [No Abstract]   [Full Text] [Related]  

  • 55. Clinical trial of the oral form of a new podophyllotoxin derivative, VP-16-213 (NSC-141540), in patients with advanced neoplastic disease.
    Nissen NI; Hansen HH; Pedersen H; Stroyer I; Dombernowsky P; Hessellund M
    Cancer Chemother Rep; 1975; 59(5):1027-9. PubMed ID: 1106845
    [No Abstract]   [Full Text] [Related]  

  • 56. [Late phase II trial of oral etoposide administered for 21 consecutive days in patients with cervical cancer. ETP 21 Study Group--Cervical Cancer Group].
    Ikeda M; Noda K; Hiura M; Tamaya T; Ozaki M; Hatae M; Ozawa M; Yamabe T; Tanaka K; Izumi R; Okada H; Ogita Y; Hoshiai H
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2249-57. PubMed ID: 9881082
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Etoposide-induced hypersensitivity reactions. Report of two cases.
    Tucci E; Pirtoli L
    Chemioterapia; 1985 Dec; 4(6):460-2. PubMed ID: 3830414
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Etoposide as single agent and in combination with cis-platinum for malignant lymphomas.
    Kroner T; Obrecht JP; Jungi WF
    Cancer Treat Rev; 1982 Jun; 9 Suppl():39-43. PubMed ID: 6889920
    [No Abstract]   [Full Text] [Related]  

  • 59. [Chemotherapy of non-small-cell bronchial cancer with a combination of Cis-diamminedichloroplatinum (II) and VP 16-213].
    Joss R; Goldhirsch A; Cavalli F; Weber W; Kaplan S; Obrecht JP; Sonntag R; Brunner KW
    Schweiz Med Wochenschr; 1981 Sep; 111(36):1331-4. PubMed ID: 7197802
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Review of etoposide single-agent activity.
    Schmoll H
    Cancer Treat Rev; 1982 Jun; 9 Suppl():21-30. PubMed ID: 6751532
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.